Search results: (10000)
News Bacterial Community Pneumonia and Its Treatment in Children
Bacterial infections remain a significant cause of child morbidity and mortality. The authors of a recent review published in the journal Pediatric Drugs focused on the treatment of complicated infections in the pediatric population. Here we bring a brief summary concerning community-acquired pneumonia.
News Overall Survival in Patients with Metastatic CRC During 1st-Line Anti-EGFR Treatment Depending on the Presence or Absence of Hypomagnesemia
Hypomagnesemia is one of the side effects of monoclonal antibody therapy against the epidermal growth factor receptor (EGFR). The study presented below examined overall survival in patients with metastatic primarily unresectable colorectal cancer (CRC) treated with anti-EGFR therapy depending on the presence or absence of hypomagnesemia.
News Options for Prevention and Treatment of Infantile Colic – A Systematic Review of Studies
The authors of the cited literature review evaluated evidence of the benefits of various preventive and therapeutic options for infantile colic. Administering probiotics appears to be a promising therapeutic strategy.
News Impact of ACEi and ARBs on Lung Function in Patients with Hypertension
Worsening respiratory functions can significantly influence the choice of antihypertensive medication. A recently published study explored whether angiotensin-converting enzyme inhibitors (ACEi) can worsen lung function and whether this effect also appears with angiotensin II receptor blockers (ARBs, i.e., sartans). These findings are crucial for clinical practice, especially in treating patients at high risk for respiratory adverse effects.
News ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being idiopathic. Severe COVID-19 can be associated with ITP manifestations where the standard first-line treatment may not be effective. In life-threatening bleeding situations, adding romiplostim has proven effective, as illustrated by the following case study from authors in Montreal, Canada.
News Development of Immune Thrombocytopenia as a Result of Past COVID-19 Illness
Immune thrombocytopenia (ITP) developing secondary to COVID-19 is a completely new experience in clinical practice. A brief summary on this topic, describing incidence and response to treatment, was published last year by authors from Cleveland.
News Analgesic Effect of Metamizole in Cold-induced Pain
The cold test is used to experimentally induce acute pain – it can thus be used, for example, to test the efficacy of analgesics. The authors of a recently published German study evaluated the analgesic effect and tolerability of metamizole compared to opioid analgesics using this method. They were led by the fact that although the drug has proven clinical efficacy and safety, it has not yet been tested using this procedure, unlike opioids.
News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients
The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.
News Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus
A recently published British study aims to provide recommendations on tapering TPO-RA in patients with immune thrombocytopenia (ITP) based on existing evidence, survey results of clinical practice among hematologists, and expert consensus.
News Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim in a patient with refractory immune thrombocytopenia (ITP). After several years of successful therapy, the medication could even be gradually discontinued while maintaining the therapeutic response.
News Newer Beta Blockers Offered for Use in Atherosclerosis Prevention
An article highlighting recent scientific findings on the beneficial effects of beta-blockers (BB) directly on the arterial wall and the potential benefit for the prevention of atherosclerotic cardiovascular disease (ASCVD) by adding BB to already established strategies for treating dyslipidemia and diabetes was published this year in the journal Current Atherosclerosis Reports.
News Will up-titration or combination with bisoprolol help to better control hypertension in amlodipine users?
Will patients with hypertension who do not achieve control of this condition with amlodipine at a dose of 5 mg benefit more from up-titration or combining it with bisoprolol? The answer to this question was sought in a study published this year by German authors.
News EMPATHY Questionnaire as a Tool for Better Personalization of Levothyroxine Doses in Patients with Primary Hypothyroidism?
The therapy for hypothyroidism consists of substitution with levothyroxine (L-T4). Failure to achieve the target thyrotropin hormone (TSH) level can be due to non-compliance (in 60% of cases) or malabsorption of the drug (in 40%). The aim of the presented Italian study was the validation of the EMPATHY questionnaire for better personalization of therapy.
News Can Thyroid Hormone Supplementation Reduce the Risk of Cognitive Disorders?
The recent systematic literature review presented below, published by authors from the California Institute of Behavioral Neurosciences and Psychology (CIBNP), focused, among other things, on potential associations between hypothyroidism and dementia and the impact of related therapeutic interventions in terms of improving cognitive functions.
News Administration of RAAS Inhibitors in Czech Patients with Heart Failure in Real Practice
A partial analysis of data from the national register of reimbursed health care focused on the epidemiology of heart failure in the Czech Republic showed how inhibitors of the renin-angiotensin-aldosterone system (RAAS), i.e., angiotensin-converting enzyme inhibitors (ACEi), AT1 receptor blockers for angiotensin II (ARBs, sartans), and angiotensin receptor and neprilysin inhibitors (ARNI), were used in real practice in the years 2012–2018 in patients with this disease.